Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

155 results about "Enterotoxin" patented technology

An enterotoxin is a protein exotoxin released by a microorganism that targets the intestines. Enterotoxins are chromosomally encoded or plasmid encoded exotoxins that are produced and secreted from several bacterial organisms. They are often heat-stable, and are of low molecular weight and water-soluble. Enterotoxins are frequently cytotoxic and kill cells by altering the apical membrane permeability of the mucosal (epithelial) cells of the intestinal wall. They are mostly pore-forming toxins (mostly chloride pores), secreted by bacteria, that assemble to form pores in cell membranes. This causes the cells to die.

Bacillus Licheniformis and Method for Detoxification of Zearalenone

The present invention discloses an isolated pure culture of a novel strain CK1 of Bacillus licheniformis, BCRC 910458, capable of detoxification of zearalenone (ZEN). Using physiological, biochemical, morphological identification and 16S rRNA gene sequence analysis methods, the strain CK1 was identified as Bacillus licheniformis. Through extracellular xylanase, CMCase protease assays and evaluations for zearalenone detoxification, the strain CK1 strain was identified to possess good ZEN-detoxifying ability, to be non-hemolytic, non-enterotoxin producing, and displayed high levels of extracellular xylanase, cellulase, and protease activities. Accordingly, Bacillus licheniformis CK1 can be applied as food and feed supplement for bio-detoxification of ZEN.
Owner:NAT TAIWAN UNIV

Recombinant engineering bacteria for efficiently expressing human growth hormone, construction method and application

The invention discloses recombinant engineering bacteria for efficiently expressing human growth hormone (hGH), a construction method and an application and provides an escherichia coli operon for expressing recombinant hGH, an expression plasmid containing an operon sequence and engineering bacteria QJSW-SZ01 (CGMCC No:7258) used for secretory expression of the recombinant hGH and obtained by transformation of the expression plasmid containing the operon. The recombinant engineering bacteria are characterized in that a coding sequence of a signal peptide of an escherichia coli heat-stable enterotoxin is changed, and rare codons of escherichia coli in the coding sequence are mutated so as to avoid formation of a secondary structure; meanwhile, an amino acid is altered on the terminal of the coding sequence so that the coding sequence is more beneficial to guidance of secretory expression of hGH; the signal peptide, an escherichia coli alkaline phosphatsae promoter (phoA promoter) and an escherichia coli T7 terminator are combined to be used as an expression control element so that the recombinant hGH is efficiently secretory-expressed in the escherichia coli in a soluble form. The recombinant engineering bacteria lay the foundation of finally developing a low-cost hGH pharmaceutical product.
Owner:吉林省奇健生物技术有限公司

Oral staphylococcus aureus filtrate preparation for improving immune function

An orally applied filtrate of staphylococcus aureus for improving immunity and increasing the number of white cells and white platelets in human body contains enterotoxin SEA, SEB, SEC, SED and TSST-1. Its advantages are sure curative effect and low toxic by-effect.
Owner:SHENYANG XIEHE GRP LTD

Antibodies for the treatment of clostridium difficile-associated infection and disease

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and / or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.
Owner:PROGENICS PHARMA INC

Dual fluorescence quantitative PCR (polymerase chain reaction) detection method and detection kit for clostridium difficile enterotoxin A and B

The invention discloses a dual fluorescence quantitative PCR (polymerase chain reaction) detection method and a detection kit for clostridium difficile enterotoxin A and B. The method comprises the steps that 1) the DNA (deoxyribonucleic acid) of a sample to be detected is extracted; 2) the DNA (deoxyribonucleic acid) of the sample to be detected is used as a template and is subjected to fluorescence quantitative PCR reaction; 3) the fluorescence of each cyclic product in the PCR reaction is subjected to fluorescence detection, and whether the sample to be detected contains clostridium difficile enterotoxin A and B or not is judged according to the lowest Ct value and the highest fluorescence value in the fluorescence detection. The invention also discloses a specific primer, a fluorescence probe and the detection kit. The dual fluorescence quantitative PCR detection method is simple, convenient and quick to operate, can detect the clostridium difficile enterotoxin A and B simultaneously, is high in detection sensitivity and specificity and can be applicable to the laboratory emergency detection of outburst epidemic caused by clostridium difficile.
Owner:ZHANGJIAGANG EENTRY EXIT INSPECTION & QUARANTINE BUREAU

Mucosal membrane receptor and uses thereof

The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4 fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens / therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis. The use of the carriers thus identified or the treatments thus identified, in a method of inducing an antigen specific intestinal mucosal immune response, and / or in the treatment of bacterial diarrhea, is a further aspect of the present invention.
Owner:UNIV GENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products